Related Experiment Video
Updated: Mar 17, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.7K
Haemarthrosis model in mice: BSS - Bleeding Severity Score assessment system
N Hakobyan1, L A Valentino2, L Cong3
1Department of Pediatrics, Rush University Medical Center, Chicago, IL, USA. narine_hakobyan@rush.edu.
Summary
This study standardized a mouse model for haemarthrosis and developed a Bleeding Severity Score (BSS) to assess new haemophilia treatments. This validated model enhances preclinical drug evaluation for joint bleeding.
Area of Science:
- Haematology
- Preclinical research
- Animal models
Background:
- Prophylactic clotting factor concentrate is the standard for preventing joint bleeds.
- New haemostatic agents require robust preclinical evaluation.
- Developing effective preclinical models is crucial for advancing haemophilia treatment.
Purpose of the Study:
- To standardize a mouse model for studying haemarthrosis.
- To develop and validate a comprehensive Bleeding Severity Score (BSS) for assessing bleeding.
- To create a reliable system for evaluating haemostatic drugs in a preclinical setting.
Main Methods:
- Standardization of a mouse haemarthrosis model using haemophilic mice.
- Development of a novel Bleeding Severity Score (BSS).
- Validation of the BSS using a mouse haemarthrosis variability model.
Main Results:
- Two key outcome measurements, extra-articular and intra-articular bleeding scores, were identified as most reliable.
- These scores were integrated into the validated Bleeding Severity Score (BSS).
- The BSS demonstrated reliability in assessing bleeding severity within the preclinical model.
Conclusions:
- The developed mouse haemarthrosis model and BSS provide a clinically relevant platform for assessing haemostatic drug efficacy.
- This standardized model significantly enhances the value of preclinical studies for novel haemophilia therapies.
- The BSS facilitates accurate and reproducible assessment of bleeding in preclinical haemophilia research.
